A study to identify clinical and inborn risk factors for development of vision impairment in patients on Ethambuol, an antituberculosis drug
Not Applicable
- Conditions
- Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
- Registration Number
- CTRI/2022/08/045044
- Lead Sponsor
- Duke NUS Program Grant Award
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Patients newly started on anti tuberculosis treatment will be included in the study.
2)Each patient will be followed up until the duration of treatment is completed depending on the treatment regime.
3)Once follow up is completed for all recruited patients, EON(Ethambutol optic neuropathy) will be defined by visual acuity assessment to test the inability of the patient to see clearly in dim light post treatment.
4)Patients who develop EON during the study period will be classified as cases and treated patients who did not develop EON will be classified as controls.
Exclusion Criteria
Patients with previous optic neuropathy of other causes and retinal pathology causing vision impairment will be excluded
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method